水化与碳酸氢钠预防肾上固定EVAR术后急性肾损伤的预试验
该预试验/可行性随机对照研究在两家中心纳入58例择期EVAR患者,评估术前高剂量碳酸氢钠负荷联合标准化水化预防急性肾损伤的安全性及可行性。主要终点为招募比例(84%)。按实际治疗分析,对照组AKI发生率33%,干预组7%;干预组未发生严重干预相关不良事件。
要点
- 高剂量碳酸氢钠联合水化在EVAR围术期安全可行,未发生严重干预相关不良事件。
- 按实际治疗分析,干预组AKI发生率7%,对照组33%,提示潜在预防效果。
- 该预试验证实开展大型确定性RCT可行,招募比例达84%。
核心结论
- 术前高剂量碳酸氢钠负荷联合标准化水化是预防EVAR相关AKI的有前景方法。
- 该预试验证实开展大型确定性RCT以验证该干预疗效具有可行性。
研究设计与样本
- 预试验/可行性随机对照研究,在两家中心开展,共纳入58例择期EVAR患者。
- 干预组接受标准化静脉水化联合术前高剂量碳酸氢钠(1 mL/kg的8.4% NaHCO3)负荷,对照组仅接受标准化静脉水化。
- 主要终点为合格患者招募入研究比例;AKI依据KDIGO和AKIN标准、基于血清肌酐和每小时尿量定义。
主要发现
- 58例患者中56例使用肾上固定装置;中位年龄75岁(范围57-89岁),女性占10%。
- 按实际治疗分析,对照组33%患者发生AKI,干预组为7%。
- 接受碳酸氢钠的患者均未发生严重干预相关不良事件;5例患者未参加30天随访。
关键数值与推荐
- AKI定义采用KDIGO和AKIN标准,基于血清肌酐和每小时尿量,参照NICE AKI推荐。
- 干预措施为术前即刻静脉给予1 mL/kg的8.4% NaHCO3负荷,联合EVAR术前后的标准化晶体液水化。
临床怎么用
- 对于接受择期EVAR(尤其使用肾上固定装置)的患者,可考虑围术期标准化水化联合术前高剂量碳酸氢钠负荷以预防AKI。
- 该策略目前证据来自小样本预试验,需等待大型RCT确认疗效后再常规推广。
局限性
- 本研究为预试验/可行性研究,样本量小(58例),不足以确证疗效。
- AKI分析为按实际治疗分析,非意向性分析。
- 5例患者未参加30天随访,存在随访缺失。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE/BACKGROUND: Up to 25% of patients undergoing elective endovascular aneurysm repair (EVAR) develop acute kidney injury (AKI), which is associated with short and long-term morbidity and mortality. There is no high quality randomised evidence regarding prevention of EVAR related AKI. METHODS: A novel AKI prevention strategy for EVAR was devised, based on best evidence and an expert consensus group. This included a bolus of high dose sodium bicarbonate (NaHCO3) immediately before EVAR (1 mL/kg of 8.4% NaHCO3) and standardised crystalloid based hydration pre- and post-EVAR. A pilot/feasibility randomised controlled trial (RCT) was performed in two centres to assess the safety of the intervention, potential impact on AKI prevention, and feasibility of a national RCT; the primary end point was the proportion of eligible patients recruited into the study. AKI was defined using "Kidney Disease Improving Global Outcomes" and "Acute Kidney Injury Network" criteria based on National Institute for Health and Clinical Excellence AKI recommendations, using serum creatinine and hourly urine output. RESULTS: Fifty-eight patients (84% of those screened; median age 75 years [range 57-89 years], 10% female) were randomised to receive the standardised intravenous hydration with (intervention) or without (control) NaHCO3. Groups were comparable in terms of AKI risk factors; 56 of 58 participants had a device with suprarenal fixation. Overall, 33% of patients in the control arm developed AKI versus 7% in the intervention arm (as treated analysis). None of the patients receiving NaHCO3 developed a serious intervention related adverse event; five patients did not attend their 30 day follow-up. CONCLUSION: Bolus high dose NaHCO3 and hydration is a promising EVAR related AKI prevention method. This trial has confirmed the feasibility of delivering a definitive large RCT to confirm the efficacy of this novel intervention, in preventing EVAR related AKI.
引用
- Saratzis A, Chiocchia V, Jiffry A, et al. HYDration and Bicarbonate to Prevent Acute Renal Injury After Endovascular Aneurysm Repair With Suprarenal Fixation: Pilot/Feasibility Randomised Controlled Study (HYDRA Pilot Trial). Eur J Vasc Endovasc Surg. 2018. PMID: 29482973. doi:10.1016/j.ejvs.2018.01.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。